Sigilon Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Sigilon Therapeutics

10/05/2023 13:01

* Sigilon Therapeutics Inc  SGTX.OQ  reported a quarterly
adjusted
loss of 23 cents​​ per share for the quarter ended in March. The
mean expectation of three analysts for the quarter was for a
loss of 23 cents per share.
    * Revenue rose 53.5% to $4.86 million from a year ago;
analysts
expected $3.10 million. 
    * Sigilon Therapeutics Inc's reported EPS for the quarter
was a
loss of 23 cents​.
    * The mean earnings estimate of analysts had risen by
about 34.3%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Sigilon Therapeutics Inc shares had fallen by 39.8% this
quarter and gained 60.0% so far this year.
    * The company reported a quarterly loss of $7.38 million.
    * Wall Street's median 12-month price target for Sigilon
Therapeutics Inc is $4.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
10 at 12:01 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.23          -0.23          Met
 Dec. 31 2022      -0.38          -0.21          Beat
 Sep. 30 2022      -0.42          -0.27          Beat
 Jun. 30 2022      -0.43          -0.44          Missed